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Abstract
Background: Oxidized low density lipoprotein plays an important role in development of foam cells in
atherosclerosis. The study was focused on regulation of primary human monocyte growth and CD11b expression
in presence of Nigella sativa oil.
Methods: Primary human monocytes were isolated from whole blood and grown at 37°C and 5% CO2 saturation
for five days prior to treatment with Nigella sativa oil. The cells were plated and washed before treatment with ox-
LDL (10 μg/ml) as positive control and combined treatment of ox-LDL (10 μg/ml) and (140 ng/ml) Nigella sativa oil.
The growth progression was monitored every 24 hours for 3 days.
Results: Macrophages showed reduced growth in comparison to monocytes 24 hours after treatment with Nigella
sativa oil. The mean cell diameter was significantly different between untreated and treated condition in
monocytes and macrophages (p < 0.001). Similarly, intracellular lipid accumulation was hindered in combined
treatment with Nigella sativa oil. This was further supported by cell surface expression analysis, where CD11b was
markedly reduced in cells treated with combination oxLDL and Nigella sativa oil compared to oxLDL alone. More
cells differentiated into macrophage-like cells when monocytes were supplemented with oxidized LDL alone.
Conclusions: The finding provides preliminary evidence on regulation of cell growth and differentiation in
monocyte and monocyte-derived macrophages by Nigella sativa oil. Further investigations need to be conducted
to explain its mechanism in human monocyte.
Background
Coronary artery disease (CAD) has continued to be the
leading cause for the world’s morbidity and mortality.
Similarly, Ministry of Health of Malaysia declared coron-
ary artery disease as the leading cause of hospital admis-
sion and non-accidental deaths over the last decade [1].
Data summary from 1994 to 2001 showed heart disease
accounted for 14% to 16% of the principal cause of death
in government hospitals in Malaysia [2].
Atherosclerosis is closely related to development of
coronary artery disease [3]. The earliest visible lesion of
atherosclerosis is the fatty streak, an aggregation of cho-
lesterol-loaded macrophages or foam cells within the
arterial wall [4]. LDL oxidation has been proven to be
associated with atherosclerosis and has been regarded as
a key step in atherogenesis [5]. Level of circulating oxi-
dized LDL was higher in patients with coronary heart dis-
ease [6]. Macrophages will continue the uptake of
oxidized LDL via scavenger receptors and further accu-
mulate intracellular cholesterol before transforming into
foam cells [7]. Differentiation of monocyte renders the
cell ready for active partici p a t i o ni ni n f l a m m a t o r ya n d
immune responses [8].
Macrophages are key players in many aspects of human
physiology and disease [9]. A hallmark of the develop-
ment of atherosclerotic plaques is the prior and concur-
rent accumulation in the arterial intima of lipoprotein
particles subject to chemical modifications. This is asso-
ciated with local inflammation in the vessel wall and
further recruitment of monocytes from the circulation.
By taking up such modified LDL (oxidized or acetylated),
monocyte-derived macrophages are turned into fat-
loaded macrophages residing in the vessel wall and
furthering the local inflammatory response. The
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several years been the focus of intensive research [10-14].
An experiment where a culture of monocytes with
oxidized LDL, resulted in increased expression of CD14,
TLR-4 (p < 0.001), there were as well as increased pro-
duction of inflammatory mediators such as IL-6, IL-1b,
a n da tal o w e re x t e n t ,T N F - a and MCP-1 factors [15].
It was evidenced that there was progressive increase in
cellular size, density, granulation and expression of sur-
face markers CD11b and CD36 during macrophage
maturation [16]. In un-stimulated monocytes and granu-
locytes, CD11b are present in an intracellular, vesicular
compartment, as well as on the cell surface. Inflamma-
tory mediators were found to stimulate a 5 to 10 fold
increase in Mac-1 (CD11b) and p150,95 on the cell sur-
face [17,18]. Oxidized LDL and minimally modified LDL
increased CD11b expression, suggesting the role CD11b
for enhanced monocyte adhesion and this was demon-
strated by prevention of monocyte adhesion by using
anti-CD11b mAb [19].
The development of natural product has been drawing
attention towards this treatment modality. Numerous stu-
dies have addressed the potential use of natural products.
I nS o u t h e r nA s i aa n dM i d d l eE a s tA s i af o rc e n t u r i e s ,
Nigella sativa L seed has been used to treat numerous dis-
eases. More than 25% of drugs used during the last 20
years are directly derived from plants, while the other 25%
are chemically altered natural products [20]. Studies have
shown that the seed and oil exert very low degree of toxi-
city [21]. The chemical composition include 32-40% fixed
oil, 0.4-0.45%% volatile oil, proteins, alkaloids, coumarins,
saponins, minerals, carbohydrate and fiber [22-24]. The
volatile oil contain 18.4-24% thymoquinone and 46% of
monoterpenes such as r-cymene and a-piene [23]. El-
Bahai et al. reported evidence of physiological and benefi-
cial cardiac hypertrophy in rats induced by long term
Nigella sativa supplementation [25]. There are also studies
that have shown its promising anti-cancer effects in ani-
mal model [24]. Recent data directly implicate signaling by
TLR4 in the pathogenesis of atherosclerosis, establishing a
key link between atherosclerosis and defense against both
foreign pathogens and endogenously generated inflamma-
tory ligands [26]. The critical role of modified LDL in
atherogenesis suggests the need to control its progression.
Therefore, modulatory effect of Nigella sativa oil on the
progression of monocyte-derived macrophage growth was
investigated.
Nigella sativa was found to exerts its effects via suppres-
sing productions of IL-6, TNF-a and NO, key pro-inflam-
matory mediators by primary macrophages, as shown in
an experiment done using Nigella sativa aqueous extract
[27]. Nigella sativa contains thymoquinone which has
been reported as a potent anti-inflammatory and cytopro-
tective agent [28]. It also has been documented that
thymoquinone is major bioactive component of Nigella
sativa to upregulate expression of hepatocyte LDL recep-
tor gene and suppress activation of HMG-CoA receptor
[29]. However, it was found that thymoquinone-rich frac-
tion extract showed higher activity compared to pure thy-
moquinone due to multiple bioactive compounds that
work synergistically [30].
Results
Isolation and identification of primary human monocytes
The cells isolated using MyPureDynabeadswere cultured
in RPMI 1640 medium for growth. Images of primary
monocytes isolated were captured using phase contrast
microscope Axiovert 25 (ZEISS) as shown in Figure 1.
The isolated monocytes were identified using Wright’s
stain smear and visualized under light microscope at
400× magnification. The cells were stained in blue and
had kidney-shaped single nucleus with light blue shaded
cytoplasm. Figure 2 shows monocyte under light micro-
scope at 400× magnification.
The oil red O stain was used to identify vesicles that
contain mainly cholesterol esters in the primary mono-
cytes. Comparison of lipid accumulation between
untreated cells and treated cells showed differences in the
staining area. Figure 3 showed positive staining in mono-
cytes following treatment with oxidized LDL. However,
addition of Nigella sativa oil led to inhibited cell growth
and impaired accumulation of oxidized LDL evidenced by
the reduced intracellular staining in treated cells (Figure
4). The cells that were not exposed to either oxidized LDL
or combination of oxidized LDL and Nigella sativa oil
were seen to grow larger than those treated with combina-
tion of oxidized LDL and Nigella sativa but had small
vesicles stained with oil red O (Figure 5).
Figure 1 Primary monocytes following isolation using
magnetic Dynabeads under 100× phase-contrast microscope.
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From the trypan blue dye cell exclusion method, the
percentage of viable cells was more than 90% with 140
ng/ml Nigella sativa oil. The IC50 value obtained in this
study was 180 ng/ml.
Effects of Nigella sativa on oxidized LDL uptake by
monocytes and macrophages
Monocytes/macrophages were grown in RPMI media for
5 days prior to addition of 10 ug/ml oxLDL or combina-
tion of 10 μg/ml oxidized LDL with 140 ng/ml Nigella
sativa oil. The cells used as control untreated and treat-
ment involved supplementation of oxidized LDL and
Nigella sativa oil. These cells were left to grow in 5%
CO2 at 37°C. The untreated cell growth was captured
using 40× phase-contrast microscope at every 24 hours
interval for 3 days as shown in Figure 6, 7, and 8,
respectively. Images of treated cells were captured at 24
hours interval for 3 days as shown in Figure 9, 10, and
11.
The observation on cell growth showed both mono-
cytes and macrophages were larger in size in the pre-
sence of oxidized LDL alone for 3 days compared to the
combined treatment with Nigella sativa oil and oxidized
LDL. There were more cells that differentiated into
macrophage-like cells in monocytes supplemented with
oxidized LDL alone.
Monocytes were found to be larger in diameter in pre-
sence of oxidized LDL throughout the timeline studied
compared to the combined treatment of oxidized LDL
and Nigella sativa (p < 0.001) (see additional file 1,
Table 1). The similar findings were seen in macrophage
diameter (p < 0.001) (see additional file 2, Table 2).
Figure 2 The arrow indicates primary monocytes stained with
Wright’s stain visualized under 400 × light microscope.
Figure 3 Monocytes-derived macrophages at day 3 post-
treatment with oxidized LDL, stained with oil red O stain and
visualized under 400 × light microscope.
Figure 4 Monocyte (arrow) supplemented with oxLDL and
Nigella sativa oil 3 days post-treatment stained with oil red O
stain and visualized under 400 × light microscope.
Figure 5 Control primary monocytes-derived macrophage left
3 days untreated visualized under 400 × light microscope.
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treatment and treatment with oxidized LDL alone were
12.9% and 15.2%, respectively. This suggested there was
reduced growth in macrophages upon exposure to
Nigella sativa oil as shown in Figure 12 and 13. How-
ever, monocyte and macrophage showed gradual growth
after 48 hours in combined treatment.
Flow cytometry analysis of CD11b expression
Flow cytometry analysis showed the expression of sur-
face marker CD11b fluorescence intensity of PE stained
cells. The finding showed reduction of the fluorescence
intensity in monocytes/macrophages treated with combi-
nation of Nigella sativa oil and oxidized LDL compared
to cells treated with oxidized LDL alone. The differential
expression was studied with 100 ng/ml and 140 ng/ml
Nigella sativa oil treatment. It also included determina-
tion of surface antigen CD11b expression in cells sup-
plemented with native LDL, PMA, PMA with oxidized
LDL (oxLDL), 140 ng/ml and 100 ng/ml Nigella sativa
were shown in Figure 14.
Discussion
Medical plants or products have been related with anti-
inflammatory properties in cell based studies [31,32].
Atherosclerosis is closely related to inflammatory pro-
cess [33-35]. Among these medical plants is Nigella
sativa L, that been reported to contain anti-oxidant and
anti-inflammatory properties [36,37]. It acts by inhibit-
ing COX and 5-LO pathways [36]. However, there is
limited documentation on effects of Nigella sativa oil
towards oxLDL intake in primary human monocyte.
We noted that Nigella sativa oil inhibited growth of
monocyte and macrophage cells without causing toxicity.
The number of viable cells was reduced to 50% when
treated with 180 ng/ml Nigella sativa oil. Monocytes
Figure 6 Monocytes/macrophages supplemented with oxidized
LDL at 24 hours.
Figure 7 Monocytes/macrophages supplemented with oxidized
LDL at 48 hours.
Figure 8 Monocytes/macrophages supplemented with oxidized
LDL at 72 hours.
Figure 9 Monocytes/macrophages supplemented with oxidized
LDL and Nigella sativa oil at 24 hours.
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Page 4 of 11were found to be larger in size in the presence of oxi-
dized LDL alone for 3 days compared to combined treat-
ment with Nigella sativa a n do x i d i z e dL D L .T h es i m i l a r
finding was seen in macrophage growth. These findings
were consistent with report by Yui et al. [38]. Oxidized
LDL was able to induce the growth of murine macro-
phages in vitro [39]. However, cell growth was found to
resume in both monocytes and macrophages after 48
hour. The declined inhibitory effect of Nigella sativa oil
could be regulated by daily supplementation of the oil
into media. Animal model studies reported daily dose of
Nigella sativa caused profound effect in decreasing lipid
peroxidation [40,41]. The effect of thymoquinone on pro-
liferation of small cell lung cancer cells was shown to
wane with time with less activity observed at 48 and 72
hours, suggesting more frequent dosing may be required
to demonstrate a sustained effect [42]. This study showed
140 ng/ml Nigella sativa oil leads to reduced lipid accu-
mulation within cells and decreased cell growth mainly
macrophages within 48 hours treatment. This was in-line
to an animal model study where rats were orally fed with
Nigella sativa at concentrations of 50 mg/kg and 100
mg/kg body weight and resulted in reduction of lipid per-
oxidation [43]. It is still unclear whether the cell growth
is regulated by expression of enzymes. Over expression
of phospholipase A(2) lipolytic has been reported in
macrophages, where it strongly increased foam cell for-
mation upon incubation with native LDL and oxLDL
[44].
The role of LDL oxidation has been claimed to be
fundamental in the formation and progression of early
atherosclerosis [45]. Human monocytes-derived macro-
phages esterified cholesterol from modified LDL more
extensively than native LDL [46]. Oxidative modification
of LDL can be induced by incubation with cell types
like monocyte/macrophage and also other cell types
such as endothelial cells and smooth muscle cells as
reported by Steinberg [13]. Oxidized LDL is taken up
Figure 10 Monocytes/macrophages supplemented with
oxidized LDL and Nigella sativa oil at 48 hours.
Figure 11 Monocytes/macrophages supplemented with
oxidized LDL and Nigella sativa oil at 72 hours.
Figure 12 Comparison on mean monocytes size within 3 days
of treatment with 10 μg/ml oxidized LDL alone (oxLDL) and
combination of 10 μg/ml oxidized LDL with 140 ng/ml Nigella
sativa (oxLDLBSO) with timeline studied.
Figure 13 Comparison on mean macrophages size within 3
days of treatment with 10 μg/ml oxidized LDL alone (oxLDL)
and combination of 10 μg/ml oxidized LDL with 140 ng/ml
Nigella sativa (oxLDLBSO) with timeline studied.
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number of macrophage cell surface proteins have been
identified which include class A scavenger receptor,
CD36 and CD68. Fuhrman et al.a l s or e p o r t e d
RAW264.7 murine macrophage cell line treatment with
oxidized LDL caused inflammatory response by stimu-
lating replication of monocyte-derived macrophages and
entry of new monocyte into lesion [47].
The accumulation of cytoplasmic lipids droplets with oil
red O staining in monocytic cells after exposure to oxi-
dized LDL had been demonstrated [4]. We found treat-
ment with combination of Nigella sativa and oxidized
LDL showed no visible intracellular lipid vesicle and the
monocyte surface was seen coated with oil red O. In addi-
tion, the morphological characteristics did not show signif-
icant development of monocyte into macrophage. The
cells treated with oxidized LDL alone had intracellular
stained lipid in several vesicles. Reduction of lipid stained
deposits in combined treatment may be explained by pre-
sence of Nigella sativa oil. It may functionally block the
oxidized LDL from inducing differentiation of monocyte
into macrophages hence blocking the uptake by scavenger
receptors. However, the actual mechanism on its action
has to be further studied. The lipid deposits in aorta had
also been observed in studies to see the effect of Nigella
sativa. Animal model study indicated supplementation of
either powder or oil form of Nigella sativa to hypercholes-
terolemic rabbits reduced lipid deposits of intimal surface
of aorta indicating inhibition of plaque formation [48].
LDL can also be oxidized by incubation of LDL with a
known catalyst of lipid peroxidation, such as copper or
iron [49]. Copper was used in the oxidation of LDL in this
study. Whereby, heavy oxidation of LDL up to 20 μgo f
protein/ml was used by Fuhrman et al. [47]. They reported
that heavy oxidation of LDL was sufficient in inducing dif-
ferentiation of monocyte into mature macrophages. It has
been reported during monocyte to macrophage differen-
tiation the expression of CD11b increased. Oxidized LDL
triggers monocyte differentiation into macrophages and
induced a distinct peak in fluorescence intensity and
increased for sMFI for CD11b [19]. Activated monocytes
in patients with active disease of Wegener’s Granulomato-
sis were shown to have an increased surface expression of
CD11b when compared to healthy control [50]. It was also
shown that together with downregulation of CD11b, the
ability of human blood monocytes to phagocytize opso-
nized E. coli also diminished [51]. These studies provide
evidence on the importance of CD11b in the activation of
monocytes. Fuhrman et al. found increased expression of
CD11b of mouse peritoneal mononuclear cells isolated on
1,2 or 3 day after intra-peritoneal injection of oxidized
LDL [47].
The flow cytometry data showed similar expression of
cell surface marker, CD11b in monocytes/macrophages
when treated with phorbolmyristate acetate (PMA) and
oxidized LDL. PMA has been used as an artificial stimu-
lator of monocyte-to-macrophage differentiation [52].
The native LDL did not induce growth of monocyte/
macrophage culture. The cells were spherical and small
as reported previously [53].
Differential expression of CD11b with certain doses of
Nigella sativa explains its role in primary human mono-
cyte-derived macrophage growth. This was shown by
reduced CD 11b expression with 100 ng/ml Nigella
sativa oil compared to 140 ng/ml. However, percentage
of cell viability was similar in both these treatments.
Further investigation would be carried out to identify
the active ingredients found in Nigella sativa oil. It has
been report the phytochemical content of Nigella sativa
seed differ due to geographical and environmental fac-
tors mainly in its phenol and fatty acid contents [54].
Therefore, seeds sown in Malaysia would be character-
ized in terms of its phytochemical composition. This
would provide precise understanding on regulation of
monocyte differentiation by the active ingredients.
Conclusions
Preliminary findings exhibited the presence of 100 ng/
ml dilution of Nigella sativa oil caused downregulation
in the differentiation of monocytes-to-macrophages
based on phenotypic change and CD11b expression.
The actual mechanism on how Nigella sativa oil exerts
its anti-lipid and CD11b expression effects need to be
further investigated.
Methods
Ethical Approval
The procedure was subject to approval by the University
Ethical Committee. Written consent was obtained from
healthy donors without medical history and without
drug treatment. Approximately 50 ml of venous blood
was collected into EDTA tubes using cannula fixed to
vein.
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Figure 14 Comparison of CD11b surface marker fluorescence
intensity with treatment. PMA = phorbol-myristate-acetate, LDL =
low density lipoprotein, oxLDL = oxidized LDL.
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The primary cells were isolated using DynabeadsMyPure
Monocyte Kit 2 for untouched human cells isolation kit
(Invitrogen Dynal AS, Oslo, Norway). The cells were
isolated from fresh whole blood collected from donor.
Preparation of Buffer 1
Buffer 1 contained either 0.1% bovine serum albumin
(BSA) or fetal calf serum (FCS) (Sigma-Aldrich, Ger-
many) and 2 mM EDTA (Invitrogen, USA) in phosphate
buffer saline (PBS) (Invitrogen GIBCO, New Zealand) at
pH 7.4. The solution was filter-sterilized with a 0.2 μm
membrane filter (WhatmanInc., USA) and stored at 4°C.
Low Density Lipoprotein
Low density lipoprotein (LDL) was purchased from Mili-
pore (Temecula, California, US). The LDL was isolated
by ultracentrifugation method by Milipore and it was
used in the study as a negative control.
LDL Oxidation (Oxidized LDL)
The LDL was diluted in phosphate-buffered saline with-
out EDTA (Invitrogen GIBCO pH 7.4 (1×) Auckland,
New Zealand) to 100 μg / m la n dd i a l y z e do v e r n i g h t
against PBS at 4°C to remove the EDTA. LDL oxidation
was done using an incubator shaker (Innova 4080)
which was maintained at 37°C with 200 rotations per
minute. LDL was incubated for 18 hours with the
freshly prepared5 mM CuSO4 (BDH AnalaR). The oxi-
dation was terminated by refrigeration at 4°C.
Nigella sativa stock preparation and working solution
The pressed oil was produced by Baraka Oil Company
in Sri Lanka. For the stock preparation, the oil was dis-
solved in 0.05% DMSO (Sigma Aldrich Co., USA). To
make a preparation of 10 mL stock, 10 μLo fN i g e l l a
sativa oil was mixed together with 5 μLD M S O .T h e
0.1% Nigella sativa stock solution was filter-sterilized
using 0.2 μm membrane filter (Whatman Inc. USA) and
stored at 4°C.
Phorbol 12-Myristate13-Acetate (PMA) preparation
The Phorbol 12-Myristate13-Acetate (PMA) (Sigma,
USA) was dissolved in DMSO and prepared to the con-
centration of 1 ng/ml. PMA. It was used in this study as
a positive control.
Culture Media Preparation
The RPMI 1640 (GIBCO) medium contained 1 mM L-
glutamine (Sigma-Aldrich, USA), 200 U/mL pen-strep
solution (Invitrogen GIBCO, New Zealand) and 10%
FCS (Sigma-Aldrich, Germany). The FCS was heat-inac-
tivated by preheating at 56°C for 30 minutes in water-
bath. The media prepared were filter-sterilized with 0.2
μm membrane filter disc (Whatman Inc., USA) and
stored at 4°C.
RPMI 1640 Medium containing 5% Lipoprotein-deficient
serum (LPDS)
This media was prepared using 1 mM L-glutamine
(Sigma-Aldrich Inc., USA), 200 U/mL pen-strep (Invi-
trogen GIBCO, New Zealand) and 5% LPDS (Milipore,
USA). The LPDS was used to replace FCS. The media
were stored at 4°C after being filter-sterilized with 0.2
μm membrane filter disc (WhatmanInc., USA).
Buffy coat preparation
The buffy coat was prepared from 50 ml of venous
blood collected in EDTA tubes. The tubes were centri-
fuged at 800 × g for 20 minutes at room temperature
(18-24°C) to obtain the separated layers of plasma, buffy
coat and red cells. The supernatant was discarded and
buffy coat was isolated from the EDTA tubes and trans-
ferred into sterile tube.
Cell isolation using DynabeadsMyPure Monocyte for
Untouched Human Cells
The monocytes were isolated using the DynabeadsMy-
Pure Monocyte isolation kit. The procedure involved
isolation of buffy coat from whole blood following cen-
trifugation. A total of 10 to 18 ml of buffy coat was
diluted in Buffer 2 to a final volume of 35 ml at 18 to
25°C at room temperature. The diluted buffy coat was
added on top of 15 ml of lymphoprep (Axis-Shield,
POC, Norway) and centrifuged at 160 × g for 20 min-
utes at room temperature. It was allowed to decelerate
without brakes. Approximately 20 ml of supernatant
was removed to eliminate platelets. Then it was centri-
fuged at 350 × g for 20 minutes at room temperature
and allowed to decelerate without brakes. The MNC
recovered from the plasma and lymphoprep interface
was transferred to a 50 ml sterile tube. The MNC was
washed once with buffer 1 by centrifugation at 400 × g
for 8 minutes at 2-8°C and then washed twice with buf-
fer 1 by centrifugation at 225 × g for 8 minutes. The
MNC was suspended at 1 × 10
7 MNC per ml in Buffer
1. A total of 100 μl MNC in Buffer 1 was transferred to
at u b ea n d2 0μl of blocking reagent and antibody mix
were added separately. This was mixed well and incu-
bated for 20 minutes at 2-8°C. The cells were washed by
adding 2 ml buffer 1 and mixed by tilting the tube sev-
eral times before centrifugation at 300 × g for 8 minutes
at 2-8°C. The supernatant was discarded and cells were
suspended in 900 μl Buffer 1 (which was pre-cooled to
2-8°C). A volume of 100 μlo fp r e - w a s h e dD e p l e t i o n
MyOneDynabeads was added and mixed well before
incubation for 15 minutes at 2-8°C by gentle tilting and
rotation. The bead-bound cells were re-suspended by
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Then, 1 ml of pre-cooled buffer 1 was added and tube
was place in the Dynal MPC-L (DynalMag 15) (Invitro-
gen, GIBCO, New Zealand) for 3 minutes. The superna-
tant was transferred to a new tube and placed again in
the magnet for another 3 minutes. The supernatant
obtained following these steps contained approximately
1×1 0
7 of untouched human monocytes.
Culture growth
The platelet-free monocytes were resuspend in 5 ml
RPMI 1640 supplemented with L-glutamine 1 mM, 200
U/ml penicillin-streptomycin and 5% heat-inactivated
fetal calf or bovine serum. The cells were incubated in a
humidified incubator with 5% CO2 and 95% air.
Staining Methods
There are two types of cell staining methods were
applied in the study. Wright’s staining was done as con-
firmatory staining for monocytes. The oil red O stain
was used to visualize cholesterol ester deposition in the
monocytes.
Wright’s staining
The Wright stain was used for the air-dried smear. It
produced the typical purple coloration of nuclei and
neutrophilic granules. Methyl alcohol is used both as a
solvent and fixative in this procedure. The nucleus and
cytoplasm expanded after staining. The smear was
immersed with Wright’s solution for 4 minutes and fol-
lowed by phosphate buffer solution for additional 9 min-
utes. Smear is then washed with water and air-dried.
Finally, Cytoseal XYL was used for mounting of smear.
Oil red O staining
Oil Red O is a lysochrome (fat-soluble dye) diazo dye
used for staining of neutral triglycerides and lipids on
frozen sections and some lipoproteins on paraffin sec-
tions. Oil Red O staining has to be performed on fresh
samples as alcohol fixation removes the lipid. Oil Red O
staining was used to view deposition of oxidized LDL in
monocytes treated with oxidized LDL alone or oxidized
LDL in the presence of Nigella sativa oil. The cell solu-
tion was air-dried on a slide before staining. A solution
was prepared with 3 parts of 0.1% oil red O in isopropyl
alcohol mixed with 2 parts of water. The slide was
immersed into oil red O solution for 20 minutes and
then dipped few times in 60% ethyl alcohol to clear the
background. Staining was continued with Harris hema-
toxylin and then the slide was placed under running
water. It was rinsed with distilled water and mounted
with glycerin jelly. Fat component was stained deep red
or deep orange, nuclei stained blue and other structures
were unstained. The staining with Wright stain and oil
red O stain for samples were done in duplicates.
Nigella sativa oil toxicity
Cell viability was done using trypan blue dye (GIBCO/
BRL) exclusion to determine the optimum concentration
of Nigella sativa oil. The concentrations of Nigella
sativa oil studied were 180 ng/ml, 140 ng/ml, 100 ng/
ml, 70 ng/ml and 35 ng/ml. The number of viable cells
was determined using hemacytometer. The cells were
trypsinized before treatment with the trypan blue dye. A
20 μl of the suspension was collected and placed on a
clean surface. Then, 20 μl of trypan blue dye (GIBCO,
BRL) was added to the cell suspension and mixed before
transferred to the edge of the haemocytometer slide and
covered by a cleaned coverslip (The hemacytometer was
earlier cleaned with 70% ethanol). The suspension mix-
ture will automatically be drawn under the coverslip by
capillarity. Any surplus fluid was then blotted and the
slide was viewed under an inverted microscope. The
cells were counted within the four corners of the grid.
Both viable and non-viable cells were counted. The
non-viable cells were stained blue. The total volume of
the cells was then calculated using the formula given.
Cell counting formula:
C=A v × 2∗ × 104 cells/ml
Where; C = cell concentration (cell/ml)
Av = average number of cells in four corners
counted
2* = dilution factor
Percentage of viable cells was counted as in the fol-
lowing formula:
Percentage of viability(%) =N v / N t × 100
Where; Nv = number of viable cells
Nt = number of cell population
Uptake of oxidized lipoprotein
The cells were grown till confluence in RPMI 1640
media. The adherent cells were transferred from 25-ml
culture flask and centrifuged at 220 × g for 8 minutes at
2-8°C. The cells were then plated in 24 well plate and
supplemented with RMPI 1640 that contained 5% lipo-
protein-deficient serum LPDS in replacement of FBS.
Then cells were left to grow until complete adherence
in humidified condition with 5% CO2 incubator at 37°C.
The modulator effect of Nigella sativa on uptake of
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140 ng/ml of Nigella sativa oil. The study design com-
prised supplementation with oxidized LDL (10 μg/ml)
alone and combination of oxidized LDL (10 μg/ml) and
Nigella sativa oil (140 ng/ml). The microscopic images
of the cells were taken at every 24 hours interval for 3
days.
Microscopic analysis
The monocyte growth images were recorded using
inverted phase-contrast microscope Axiovert 25 (ZEISS)
pre-treatment, post-treatment day-1 and post-treatment
day-5. The cells were stained using oil red O to visualize
lipid engorgement into cells. The growth was deter-
mined based on cell diameter using Pro-plus software
and type with positive staining of oil red O. Growth rate
was determined based on difference in cell diameter
before and after treatment.
Flow cytometry analysis
Sample was prepared for cell surface antigen detection,
CD11b using flow cytometry analysis by FACS Canto
analyzer. The surface marker CD11b was detected using
monoclonal antibody (BD Biosciences. San Jose36-37,
Canada) reacted against CD11b antigen on monocyte
surfaces. Analysis was done using software FACS Diva
Version 6.1.2.
The sample preparation was done by isolating at least
1×1 0
4 cells into a 15 ml conical tube. The tube was
centrifuged and media was removed to leave the cell
pellets. The cells were then washed once with PBS at
pH 7.4. This was followed by addition of 20 ug of
CD11b monoclonal antibodies (BD Biosciences, Canada)
into the tube and the tube was then incubated for 30
minutes in a dark place. After incubation the samples
were washed again twice with PBS to remove excess
antibody. The cells were then suspended in PBS for flow
cytometry analysis.
Expression of surface marker CD11b was studied
within 72 hours. The data obtained on 10,000 cells were
stored in list-mode data files and analyzed by FACS
Diva Version 6.1.2 software. The instrument was cali-
brated using CST Setup Beads (BD Biosciences, San
Jose, CA). Monocyte subpopulation gating was based on
forward scatter versus side scatter plot. To confirm the
monocyte subpopulation, PE CD11b against side scatter
was plotted.
The test samples included negative control (native
LDL), positive controls (PMA, PMA with oxLDL), cells
treated with 100 ng/ml dilution of Nigella sativa oil and
treated with 140 ng/ml of Nigella sativa oil as shown in
Figure 3, 4, 5, 6, 7, 8.
Statistical analysis
Each experiment was done in triplicates. Analysis of
results was done using t-test. All values were expressed
as means ± standard deviation. Values of p < 0.05 were
considered as significant.
Additional material
Additional file 1: Mean differences in monocyte growth. (Results
were expressed as mean ± s.d. p < 0.001 indicates statistically significant
different. The experiments were done in triplicates). OxLDL = oxidized
LDL, OxLDLNSO = oxidized LDL combined with NSO, Mean = mean
diameter of cells in μm.
Additional file 2: Mean differences in macrophage growth. (Results
were expressed as mean ± s.d. p < 0.001 indicates statistically significant
different. The experiments were done in triplicates). OxLDL = oxidized
LDL, OxLDLNSO = oxidized LDL combined with NSO, Mean = mean
diameter of cells in μm.
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